Report cover image

Global Overactive Bladder Treatment Market Size study, by Drug Type (Anticholinergic [Solifenacin, Oxybutynin, Tolterodine, Darifenacin], Mirabegron), Botox, Neuromodulation, by Disease Type (Idiopathic OAB, Neurogenic OAB) and Regional Forecasts 2024-203

Publisher Factview Research
Published Jun 27, 2025
Length 285 Pages
SKU # FAVR20179476

Description

The global Overactive Bladder Treatment Market is valued at approximately USD 3.8 billion in 2024 and is poised to grow at a compound annual growth rate (CAGR) of 4.0% during the forecast period from 2024 to 2034. Overactive bladder (OAB) represents a complex yet increasingly prevalent medical condition that severely impacts the quality of life. With symptoms ranging from frequent urination to involuntary leakage, OAB drives a significant demand for innovative therapeutic interventions.

This growing demand is met by a surge in pharmacological advancements and the integration of cutting-edge technologies, including neuromodulation devices and botulinum toxin treatments. Anticholinergic drugs such as Solifenacin, Oxybutynin, and Tolterodine remain the cornerstone of therapy, while Mirabegron is gaining traction as a beta-3 adrenergic agonist, providing a safer and more tolerable alternative. Concurrently, neuromodulation techniques are being widely adopted as minimally invasive solutions for managing refractory cases, highlighting the market's dynamic innovation landscape.

The Overactive Bladder Treatment Market is further shaped by a rising geriatric population, a demographic inherently susceptible to OAB, and a heightened awareness of the condition's psychological and physiological impact. Despite these advancements, the market faces challenges, including limited patient adherence to anticholinergic medications due to side effects and the high cost associated with advanced therapeutic modalities such as neuromodulation and Botox injections.

Regionally, North America leads the global market due to its robust healthcare infrastructure, substantial investments in research and development, and high prevalence rates of OAB. Europe follows closely, benefiting from favorable reimbursement policies and increasing adoption of advanced treatments. Meanwhile, the Asia-Pacific region is expected to exhibit the fastest growth, driven by a growing geriatric population, rising healthcare expenditures, and improved access to innovative therapeutic solutions in emerging economies such as China and India.

Major market players included in this report are:
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Medtronic plc
  • AbbVie Inc.
  • Allergan plc
  • Urovant Sciences
  • Endo Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Ipsen Pharma
  • Coloplast A/S
  • Viatris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Glenmark Pharmaceuticals
  • Sanofi
  • Laborie Medical Technologies
The detailed segments and sub-segment of the market are explained below:

By Drug Type
  • Anticholinergic
Solifenacin

Oxybutynin

Tolterodine

Darifenacin
  • Mirabegron
By Botox

By Neuromodulation

By Disease Type
  • Idiopathic OAB
  • Neurogenic OAB
By Region:

North America
  • U.S.
  • Canada
Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Rest of Europe
Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Rest of Asia Pacific
Latin America
  • Brazil
  • Mexico
Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa
Years considered for the study are as follows:
  • Historical year – 2022
  • Base year – 2024
  • Forecast period – 2024 to 2034
Key Takeaways:
  • Market estimates and forecasts for 10 years from 2022 to 2032.
  • Annualized revenues and regional-level analysis for each market segment.
  • Comprehensive geographical insights with country-level analysis for major regions.
  • Competitive landscape profiling and analysis of major market players.
  • Key business strategies and recommendations for future market approaches.

Table of Contents

285 Pages
Chapter 1. Global Overactive Bladder Treatment Market Executive Summary
1.1. Global Overactive Bladder Treatment Market Size & Forecast (2024-2034)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Drug Type
1.3.1.1. Anticholinergic
Solifenacin
Oxybutynin
Tolterodine
Darifenacin
Mirabegron
1.3.2. By Botox
1.3.3. By Neuromodulation
1.3.4. By Disease Type
Idiopathic OAB
Neurogenic OAB
1.4. Key Trends
1.5. Recession Impact
1.6. Investment Analysis
1.7. Investment Rationale
1.8. Analyst Recommendation & Conclusion
Chapter 2. Global Overactive Bladder Treatment Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Consumer’s Perspective)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Overactive Bladder Treatment Market Dynamics
3.1. Market Drivers
3.1.1. Rising Healthcare Spending
3.1.2. Expanding Geriatric Population
3.1.3. Increasing Focus on Patient-Centric Nutritional Care
3.2. Market Challenges
3.2.1. Limited Patient Adherence to Anticholinergic Medications
3.2.2. High Costs Associated with Advanced Therapeutic Modalities
3.3. Market Opportunities
3.3.1. Integration of Innovative Delivery Systems
3.3.2. Research-Backed Formulations
3.3.3. Growth in Emerging Economies (China, India)
Chapter 4. Global Overactive Bladder Treatment Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Overactive Bladder Treatment Market Size & Forecasts by Drug Type 2024-2034
5.1. Segment Dashboard
5.2. Global Overactive Bladder Treatment Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
5.2.1. Anticholinergic
5.2.1.1. Solifenacin
5.2.1.2. Oxybutynin
5.2.1.3. Tolterodine
5.2.1.4. Darifenacin
5.2.2. Mirabegron
Chapter 6. Global Overactive Bladder Treatment Market Size & Forecasts by Botox 2024-2034
6.1. Segment Dashboard
6.2. Global Overactive Bladder Treatment Market: Botox Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
Chapter 7. Global Overactive Bladder Treatment Market Size & Forecasts by Neuromodulation 2024-2034
7.1. Segment Dashboard
7.2. Global Overactive Bladder Treatment Market: Neuromodulation Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
Chapter 8. Global Overactive Bladder Treatment Market Size & Forecasts by Disease Type 2024-2034
8.1. Segment Dashboard
8.2. Global Overactive Bladder Treatment Market: Disease Type Revenue Trend Analysis, 2022 & 2032 (USD Million/Billion)
8.2.1. Idiopathic OAB
8.2.2. Neurogenic OAB
Chapter 9. Global Overactive Bladder Treatment Market Size & Forecasts by Region 2024-2034
9.1. North America Overactive Bladder Treatment Market
9.1.1. U.S. Overactive Bladder Treatment Market
9.1.1.1. Drug Type Breakdown Size & Forecasts, 2024-2034
9.1.1.2. End User Breakdown Size & Forecasts, 2024-2034
9.1.2. Canada Overactive Bladder Treatment Market
9.2. Europe Overactive Bladder Treatment Market
9.2.1. UK Overactive Bladder Treatment Market
9.2.2. Germany Overactive Bladder Treatment Market
9.2.3. France Overactive Bladder Treatment Market
9.2.4. Spain Overactive Bladder Treatment Market
9.2.5. Italy Overactive Bladder Treatment Market
9.2.6. Rest of Europe Overactive Bladder Treatment Market
9.3. Asia-Pacific Overactive Bladder Treatment Market
9.3.1. China Overactive Bladder Treatment Market
9.3.2. India Overactive Bladder Treatment Market
9.3.3. Japan Overactive Bladder Treatment Market
9.3.4. Australia Overactive Bladder Treatment Market
9.3.5. South Korea Overactive Bladder Treatment Market
9.3.6. Rest of Asia Pacific Overactive Bladder Treatment Market
9.4. Latin America Overactive Bladder Treatment Market
9.4.1. Brazil Overactive Bladder Treatment Market
9.4.2. Mexico Overactive Bladder Treatment Market
9.4.3. Rest of Latin America Overactive Bladder Treatment Market
9.5. Middle East & Africa Overactive Bladder Treatment Market
9.5.1. Saudi Arabia Overactive Bladder Treatment Market
9.5.2. South Africa Overactive Bladder Treatment Market
9.5.3. Rest of Middle East & Africa Overactive Bladder Treatment Market
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Astellas Pharma Inc.
10.1.2. Pfizer Inc.
10.1.3. Medtronic plc
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. Astellas Pharma Inc.
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Pfizer Inc.
10.3.3. Medtronic plc
10.3.4. AbbVie Inc.
10.3.5. Allergan plc
10.3.6. Urovant Sciences
10.3.7. Endo Pharmaceuticals Inc.
10.3.8. Teva Pharmaceutical Industries Ltd.
10.3.9. Ipsen Pharma
10.3.10. Coloplast A/S
10.3.11. Viatris Inc.
10.3.12. Sun Pharmaceutical Industries Ltd.
10.3.13. Glenmark Pharmaceuticals
10.3.14. Sanofi
10.3.15. Laborie Medical Technologies
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us